期刊
JOURNAL OF PATHOLOGY
卷 254, 期 3, 页码 229-238出版社
WILEY
DOI: 10.1002/path.5683
关键词
thoracic aortic aneurysm; bicuspid aortic valve; biomarkers; cellular phenotype; arterial remodeling; oxidative stress; clinical trials
资金
- FEDER [PI20/01103]
- CAM [PEJD-2019-PRE/BMD-16992, 2018-T2/BMD-11561]
- Instituto de Salud Carlos III
Thoracic aortic aneurysm (TAA) develops silently and asymptomatically, usually diagnosed incidentally, and lacks effective drugs and biological markers for early identification. Research aims to define novel markers for TAA and discuss the potential of previously identified molecules for early diagnosis/prognosis.
Thoracic aortic aneurysm (TAA) develops silently and asymptomatically and is a major cause of mortality. TAA prevalence is greatly underestimated, it is usually diagnosed incidentally, and its treatment consists mainly of prophylactic surgery based on the aortic diameter. The lack of effective drugs and biological markers to identify and stratify TAAs by risk before visible symptoms results from scant knowledge of its pathophysiological mechanisms. Here we integrate the structural impairment affecting non-syndromic non-familial TAA with the main cellular and molecular changes described so far and consider how these changes are interconnected through specific pathways. The ultimate goal is to define much-needed novel markers of TAA, and so the potential of previously identified molecules to aid in early diagnosis/prognosis is also discussed. (c) 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据